(Q34384341)

1 August 2017

1 reference

title

Predicting the impact of physiological and biochemical processes on oral drug bioavailability (English)

1 reference

1 August 2017

1 reference

Agoram B

1

1 reference

1 August 2017

Woltosz WS

series ordinal

2

1 reference

1 August 2017

Bolger MB

series ordinal

3

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 October 2001

1 reference

Advanced Drug Delivery Reviews

1 August 2017

1 reference

1 August 2017

50 Suppl 1

1 reference

1 August 2017

S41-67

1 reference

Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Theoretical Model Studies of Drug Absorption and Transport in the Gastrointestinal Tract II

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Theoretical Model Studies of Drug Absorption and Transport in the Gastrointestinal Tract I

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Theoretical Model Studies of Drug Absorption and Transport in the GI Tract III

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Quantitative Interpretation of In Vivo Buccal Absorption of n-Alkanoic Acids by the Physical Model Approach

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Physicochemical model for dose-dependent drug absorption

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Use of a pharmacokinetic model incorporating discontinuous gastrointestinal absorption to examine the occurrence of double peaks in oral concentration-time profiles

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Discontinuous oral absorption pharmacokinetic model and bioavailability of 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)uracil (L-FMAU) in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Development of predictive pharmacokinetic simulation models for drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

A compartmental absorption and transit model for estimating oral drug absorption.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Predicting fraction dose absorbed in humans using a macroscopic mass balance approach

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Prediction of the plasma concentration profiles of orally administered drugs in rats on the basis of gastrointestinal transit kinetics and absorbability

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

A heterogeneous tube model of intestinal drug absorption based on probabilistic concepts

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Heterogeneous tube model for the study of small intestinal transit flow

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption--theoretical approach

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

First-pass metabolism of midazolam by the human intestine.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Drug exsorption from blood into the gastrointestinal tract

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

The intestinal dialysis of intravenously administered phenytoin by oral activated charcoal in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Estimation of the relative contribution of the transcellular and paracellular pathway to the transport of passively absorbed drugs in the Caco-2 cell culture model

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Membrane transport of drugs in different regions of the intestinal tract of the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Passive diffusion of weak organic electrolytes across Caco-2 cell monolayers: uncoupling the contributions of hydrodynamic, transcellular, and paracellular barriers.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

First-pass elimination. Basic concepts and clinical consequences

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Individual variation in first-pass metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Human cytochromes P-450.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Multiple forms of human cytochrome P-450

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Interspecies scaling of interferon disposition and comparison of allometric scaling with concentration-time transformations.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Models of hepatic drug elimination

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Predicting the hepatic clearance of xenobiotics in humans from in vitro data

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Prediction of interindividual variation in drug plasma levels in vivo from individual enzyme kinetic data and physiologically based pharmacokinetic modeling

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

CYP3A gene expression in human gut epithelium

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Localization, distribution, and induction of xenobiotic-metabolizing enzymes and aryl hydrocarbon hydroxylase activity within lung

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Intestinal Drug Absorption and Metabolism I: Comparison of Methods and Models to Study Physiological Factors of In Vitro and In Vivo Intestinal Absorption

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Saturable small intestinal drug absorption in humans: modeling and interpretation of cefatrizine data

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

The barrier function of CYP3A4 and P-glycoprotein in the small bowel

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Application of moment analysis to nonlinear drug disposition described by the Michaelis-Menten equation.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Michaelis-Menten metabolite formation kinetics: equations relating area under the curve and metabolite recovery to the administered dose.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Theoretical Michaelis-Menten elimination model for propranolol

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Bioavailability of sustained release propranolol formulations

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Biology of membrane transport proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

First-pass accumulation of salicylic acid in gut tissue after absorption in anesthetized rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

We may not measure the correct intestinal wall permeability coefficient of drugs: alternative absorptive clearance concept

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Hepatic clearance of drugs. II. Experimental evidence for acceptance of the “well-stirred” model over the “parallel tube” model using lidocaine in the perfused rat liverin situ preparation

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Liver circulation and function

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

A computer simulation of the food effect: transient changes in hepatic blood flow and Michaelis-Menten parameters as mediators of hepatic first pass metabolism and bioavailability of propranolol

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Dose-dependent elimination of propranolol and its major metabolites in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Propranolol: pooled Michaelis-Menten parameters and the effect of input rate on bioavailability.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Saturable first-pass kinetics of propranolol.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Comparison of the pharmacokinetics of intravenous dl-propranolol in borderline and permanent hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Plasma concentrations and bioavailability of propranolol by oral, rectal, and intravenous administration in man

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Food effects on propranolol systemic and oral clearance: support for a blood flow hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Midazolam: the first water-soluble benzodiazepine. Pharmacology, pharmacokinetics and efficacy in insomnia and anesthesia

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Interaction between grapefruit juice and midazolam in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Midazolam alpha-hydroxylation by human liver microsomes in vitro: inhibition by calcium channel blockers, itraconazole and ketoconazole.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Dose dependent pharmacokinetics of midazolam.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Clinical pharmacokinetics of digoxin 1980.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Bioavailability of drugs: the digoxin dilemma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Clinical Pharmacokinetics of Digoxin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Immunomodulating properties of 5,20 alpha (R)-dihydroxy-6 alpha,7 alpha-epoxy-1-oxo-(5 alpha)-whitha-2,24-dienolide and solasodine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Pharmacokinetic comparison of pindolol with other beta-adrenoceptor-blocking agents

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Variable first-pass elimination of propranolol following single and multiple oral doses in hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Drug-grapefruit juice interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

Modulation of P-glycoprotein expression by cytochrome P450 3A inducers in male and female rat livers.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2801%2900179-X

7 January 2021

10.1016/S0169-409X(01)00179-X

Identifiers

DOI

1 reference

1 August 2017

1 reference